Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%

The story
Lipfendra, the first once-daily oral PCSK9 inhibitor, was shown to reduce LDL cholesterol by roughly 56% to 60% when combined with statins.
How other outlets covered this
Compare allAlto found this story at 2 outlets. Same event, different framing — compare the headlines.
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events